Failure of PM is less often reported, but may feature in a second wave of negative or cautionary reports following early data and initial clinical promise, with increasing watchfulness expressed by many succeeding studies (see Table 1 for the use of quinidine in epilepsies due to gain‐of‐function mutations in KCNT1 as an example). This evidence concerns the gene KCNT1 and epilepsy.